Today: 5 February 2026
Subscribe
Browse Category

NASDAQ:AKAN News 5 December 2025 - 12 December 2025

Akanda Corp (AKAN) Stock News Today: Why Shares Are Jumping on Dec. 12, 2025 — Latest Forecasts, Filings, and What to Watch

Akanda Corp (AKAN) Stock News Today: Why Shares Are Jumping on Dec. 12, 2025 — Latest Forecasts, Filings, and What to Watch

Updated: December 12, 2025 Akanda Corp (NASDAQ: AKAN ) is back on traders’ radars Friday after a sharp premarket move and unusually heavy volume for a micro-cap stock. Early on Dec. 12, 2025 , AKAN showed up on multiple “top movers” lists, with premarket quotes and percentage gains shifting quickly as trading activity accelerated. Stock Analysis What makes AKAN especially…
12 December 2025
····
Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Akanda Corp (AKAN) Stock Soars After Shareholder Vote: Reverse Merger, Mexico Towers and 2025–2030 Forecasts

Published: December 5, 2025 Akanda Corp’s Nasdaq-listed shares (ticker: AKAN) are back in the spotlight after a dramatic late‑week move. On Thursday evening, the micro‑cap stock surged about 45% in after‑hours trading to roughly $1.37, after the company disclosed that shareholders had approved sweeping capital‑structure changes linked to its reverse merger with First Towers & Fiber Corp and a package…
5 December 2025
·····

Stock Market Today

  • Boston Scientific Shares Dive 17.5% on Disappointing 2026 Profit Guidance
    February 4, 2026, 6:32 PM EST. Boston Scientific's stock plunged 17.5% to $75.59 on Feb. 4 after its Q4 earnings beat estimates but cautious 2026 profit guidance disappointed investors. The medical-device maker delivered 16% sales growth and 14% adjusted EPS growth in Q4, outperforming Wall Street expectations. However, weak guidance for the first quarter and 2026 EPS trimmed investor optimism, with EPS projections falling slightly short. Trading volume surged 581% above its three-month average, reflecting the sharp selloff. Despite the setback, Boston Scientific's Cardiovascular segment grew sales 18%, MedSurg unit revenues rose 12%, and management forecasted $4.2 billion in free cash flow for 2026. The decline was company-specific; peers Medtronic and Stryker showed smaller losses. Investors weigh today's reaction as overdone given Boston Scientific's consistent long-term growth and double-digit sales gains across 12 quarters.
Go toTop